# Study of ZGGS34 in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07258121/  
OnCo record `nct07258121` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ZG006 in advanced solid tumours, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.

## Summary

Study of ZGGS34 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07258121 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 400 participants planned, started 2025-12-31 and due to reach its primary completion in 2028-12. Interventions recorded: ZG006.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07258121
- Phase: 1/2
- Setting: A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZGGS34 in Participants With Advanced Solid Tumors
- Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Enrolled: 400

## Sources

- ClinicalTrials.gov NCT07258121: https://clinicaltrials.gov/study/NCT07258121

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [ZG006](https://onco.cc/drugs/zg006/)
- companies: [Suzhou Zelgen Biopharmaceuticals](https://onco.cc/companies/zelgen/)

---
JSON: https://onco.cc/api/v1/entities/nct07258121.json